AGO2 and breast neoplasm: Interestingly, tumor samples with a breast tumor type categorized as luminal B (Figure 1A) and an ERα+/PGR− receptor status (Figure 1B) demonstrated high AGO2 expression levels compared to samples with luminal A/ERα+/PGR+ receptor status.